US20080091262A1 - Drug delivery after biodegradation of the stent scaffolding - Google Patents

Drug delivery after biodegradation of the stent scaffolding Download PDF

Info

Publication number
US20080091262A1
US20080091262A1 US11582706 US58270606A US2008091262A1 US 20080091262 A1 US20080091262 A1 US 20080091262A1 US 11582706 US11582706 US 11582706 US 58270606 A US58270606 A US 58270606A US 2008091262 A1 US2008091262 A1 US 2008091262A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
stent
scaffolding
method according
anti
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11582706
Inventor
David C. Gale
Bin Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Cardiovascular Systems Inc
Original Assignee
Abbott Cardiovascular Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148Materials at least partially resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41Anti-inflammatory agents, e.g. NSAIDs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Abstract

Disclosed herein is a stent comprising: a bioabsorbable polymeric scaffolding; and a coating comprising a bioabsorbable material on at least a portion of the scaffolding, wherein the degradation rate of all or substantially all of the bioabsorbable polymer of the scaffolding is faster than the degradation rate of all or substantially all of the bioabsorbable material of the coating.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention generally relates to a stent for treating a disorder with a drug over a period of time extending beyond biodegradation of the stent scaffolding.
  • 2. Description of the Background
  • In particular, the invention relates to radially expandable endoprostheses that are adapted to be implanted in a bodily lumen. An “endoprosthesis” corresponds to an artificial device that is placed inside the body. A “lumen” refers to a cavity of a tubular organ such as a body lumen. A stent is an example of such an endoprosthesis. Stents are generally cylindrically shaped devices which function to hold open and sometimes expand a segment of a body lumen or other anatomical lumen such as urinary tracts and bile ducts. Stents are often used in the treatment of atherosclerotic stenosis in body lumens. “Stenosis” refers to a narrowing or constriction of the diameter of a bodily passage or orifice. In such treatments, stents reinforce body vessels and prevent restenosis following angioplasty. “Restenosis” refers to the reoccurrence of stenosis in a body lumen or heart valve after it has been subjected to angioplasty or valvuloplasty.
  • The treatment of a diseased site or lesion with a stent involves both delivery and deployment of the stent. “Delivery” refers to introducing and transporting the stent through a bodily lumen to the treatment area in a body lumen. “Deployment” corresponds to the expanding of the stent within the lumen at the treatment area. Delivery and deployment of a stent are accomplished by positioning the stent at one end of a catheter, inserting the end of the catheter through the skin into a bodily lumen, advancing the catheter in the bodily lumen to a desired treatment location, expanding the stent at the treatment location, and removing the catheter from the lumen. In the case of a balloon expandable stent, the stent is mounted about a balloon disposed on the catheter. Mounting the stent typically involves compressing or crimping the stent onto the balloon. The stent is then expanded by inflating the balloon. The balloon may then be deflated and the catheter withdrawn. In the case of a self-expanding stent, the stent may be secured to the catheter via a retractable sheath or a sock.
  • When the stent is in a desired bodily location, the sheath may be withdrawn allowing the stent to self-expand. This requires a sufficient degree of strength and rigidity or stiffness. In addition to having adequate radial strength, the stent should be longitudinally flexible to allow it to be maneuvered through a tortuous vascular path.
  • Thus, a stent is typically composed of scaffolding that includes a pattern or network of interconnecting structural elements or struts. The scaffolding can be formed of tubes, or sheets of material rolled into a cylindrical shape. The scaffolding is designed to allow the stent to be radially expandable. The pattern is generally designed to maintain the longitudinal flexibility and radial rigidity required of the stent. Longitudinal flexibility facilitates delivery of the stent and radial rigidity is needed to hold open a bodily lumen. A medicated stent may be fabricated by coating the surface of either a metallic or polymeric scaffolding with a polymeric carrier that includes a bioactive agent. The polymeric scaffolding may also serve as a carrier of bioactive agent.
  • In many treatment applications of stents, the presence of a stent in a body may be necessary for a limited period of time until its intended function of, for example, maintaining vascular patency and/or drug delivery is accomplished. Thus, stents are often fabricated from biodegradable, bioabsorbable, and/or bioerodable materials such that they completely erode only after the clinical need for them has ended. In addition, a stent should also be capable of satisfying the mechanical requirements discussed above during the desired treatment time.
  • A polymeric stent should be mechanically stable throughout the range of stress experienced during use. In addition to mechanical stability, a stent should have a sufficient rate of biodegradability or erosion as dictated by a treatment regimen. However, one of the major clinical challenges of bioabsorbable stents is adequately suppressing inflammatory responses triggered by the degradation of the stent. The embodiments of the invention address this and other concerns.
  • SUMMARY OF THE INVENTION
  • Disclosed herein is a stent comprising: a bioabsorbable polymeric scaffolding; and a coating comprising a bioabsorbable material on at least a portion of the scaffolding, wherein the degradation rate of all or substantially all of the bioabsorbable polymer of the scaffolding is faster than the degradation rate of all or substantially all of the bioabsorbable material of the coating.
  • Also disclosed herein is a method treating a body lumen, the method comprising: providing a stent comprising a scaffolding that degrades at a faster rate than a coating on the scaffolding; and deploying the stent at a treatment area in a body lumen.
  • Further, disclosed herein is a method of treating a body lumen, the method comprising: deploying a first stent at a treatment area, wherein the first stent includes a bioabsorbable polymeric scaffolding and a coating having a bioabsorbable material on at least a portion of the scaffolding, and wherein the degradation rate of all or substantially all of the bioabsorbable polymer of the scaffolding is faster than the degradation rate of all or substantially all of the bioabsorbable material of the coating; and deploying a second stent in at least a portion of the treatment area.
  • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 depicts a stent.
  • FIG. 2( a) depicts a cross-section of a stent implanted in a body lumen, the stent having a scaffolding and a coating.
  • FIG. 2( b) depicts the stent after endothelialization of the stent in the body lumen.
  • FIG. 2( c) depicts the stent after endothelialization of the stent and degradation of the scaffolding.
  • FIG. 3 depicts a second stent that is implanted at a treatment area of a first stent.
  • DETAILED DESCRIPTION
  • A common disorder associated with mechanical modification of a vessel, such as by a balloon or stenting is restenosis. A number of cellular mechanisms have been proposed that lead to restenosis of a vessel, such as inflammatory response to injury and foreign body presence.
  • Inflammation is a defensive, biological response to injury, infection, or an abrupt change in tissue homeostasis. In nature, inflammatory responses are designed to destroy, dilute and isolate injurious agents and then lead to recovery and repair of the affected tissue. Vascular inflammation is the first stage of the inflammatory response, developing after the initial contact with the stimulus and continuing sometimes for several days. The presence of a stimulatory agent in the blood or in the tissue triggers the body's response through endothelial cells. The endothelial cell layer is the innermost layer of larger vessels and the only cell layer of the smallest vessels, the capillaries.
  • Additionally, the presence of a biodegradable foreign body, such as a biodegradable stent in a vessel can lead to or aggravate an inflammatory response, thus leading to more aggressive restenosis. Biodegradation refers generally to changes in physical and chemical properties that occur (e.g., in a polymer) upon exposure to bodily fluids as in a vascular environment. The changes in properties may include a decrease in molecular weight, deterioration of mechanical properties, and decrease in mass due to erosion or absorption. The decrease in molecular weight may be caused by chemical reactions of bodily fluids with the polymer, for example, hydrolysis and/or metabolic processes. By-products of such degradation reactions can be responsible for inciting inflammation. For example, by-products of hydrolysis are produced when polymer molecules are cleaved into component parts by the addition of water. Various byproducts of degradation of biodegradable polymers are known to incite an inflammatory response. For example, lactic acid, a degradation by-product of poly(lactic acid) polymers, is known to cause an inflammatory response.
  • Furthermore, the release of by-products into the body from a biodegradable stent occurs continuously from the time of first exposure to bodily fluids to a time when the stent is either completely degraded and eliminated or removed from the body. It follows that throughout this time frame, the body is continuously exposed to inflammation-inciting by-products. Therefore, it is desirable for the stent to degrade rapidly once the need for support of the lumen has expired.
  • Described herein is a drug-delivery stent that allows delivery of drug even after the stent scaffolding has degraded. Thus, the stent scaffolding need not remain in the body lumen to deliver drug. The stent scaffolding may be made to degrade rapidly and completely or substantially completely disappear once the need for support of the lumen has expired. The drug-delivery stent described herein includes one or more drugs for treating a vascular disorder or a related disorder. The drugs, for example, can be a combination of at least one anti-proliferative agent, at least one anti-inflammatory agent, and optionally other types of bioactive agents.
  • A biodegradable stent and drug delivery can remain in the body for a duration of time at least until its intended function of, for example, maintaining vascular patency and drug delivery is accomplished. Biodegradable polymers are used to form the stent, such that the entire stent can be made to disappear after the process of degradation, erosion, or absorption. In some embodiments, very negligible traces of polymer or residue are left behind. The duration is typically in the range of 6-12, 6-18, or 6-24 months, for example. The time needed to maintain vascular patency can be shorter than the drug delivery time.
  • The term “stent” is intended to include, but is not limited to, self-expandable stents, balloon-expandable stents, stent-grafts, and grafts. The structure of the stent can be of virtually any design. A stent, for example, may include a pattern or network of interconnecting structural elements or struts. FIG. 1 depicts an example of a three-dimensional view of a stent 100. The stent may have any pattern that includes a number of interconnecting elements or struts 110. As shown in FIG. 1 the geometry or shape of stents vary throughout its structure. In some embodiments, a stent may be formed from a tube by laser cutting the pattern of struts into the tube. The stent may also be formed by laser cutting a polymeric sheet, rolling the pattern into the shape of the cylindrical stent, and providing a longitudinal weld to form the stent.
  • A stent 200 according to one embodiment of the invention includes a bioabsorbable polymeric scaffolding 210 and a coating material 220 on at least a portion of the scaffolding 210, as depicted in FIG. 2( a). Coating material 220 may include a drug and a bioabsorbable polymer. The degradation rate of at least a portion of scaffolding 210 is faster than the degradation rate of coating material 220. In one embodiment, the degradation rate of all or substantially all of scaffolding 210 is faster than the degradation rate of all or substantially all of coating material 220. Thus, the degradation time of all or substantially all scaffolding 210 is shorter than the degradation time of all or substantially all coating material 220. By providing a scaffolding 210 that has a faster degradation rate than its coating 220, the scaffolding 210 degrades first, while coating material 220 continues to deliver drug. In one embodiment, coating material 220 continues to deliver drug after scaffolding 210 has completely degraded. FIG. 2( b) depicts a cross-section of a stent implanted in body lumen 230. FIG. 2( b) depicts stent 200 after endothelialization of stent 200 in lumen wall 240. In one embodiment, all or substantially all of coating material 220 degrades faster than all or substantially all of scaffolding 210. In another embodiment, coating material 220 continues to elute drugs even after vascular patency has expired. The coating layer remains after there is no longer any stent vascular patency.
  • Turning now to FIG. 2( c), with continual reference to FIG. 2( b), coating material 220 remains lodged in lumen wall 240 after scaffolding 210 substantially degrades. Because coating material 220 can be made to deliver drug even after the disintegration of scaffolding 210, the invention enables stent 200 to release drug for an extended period of time throughout the life of stent 200 while scaffolding 210 degrades, and if desired, long after scaffolding 210 degrades. In one embodiment, stent 200 delivers drug for over 50% of the life of scaffolding 210. In another embodiment, stent 200 delivers drug for over 80% of the life of scaffolding 210. In yet another embodiment, stent 200 delivers drug for the entire life of scaffolding 210, or 100% of the life of scaffolding 210. Thus, after the entire scaffolding 210 has completely degraded, coating material 220 may be designed to continue to deliver drug, as depicted in FIG. 2( c).
  • In one embodiment, upon deployment of stent 200 in treatment area, scaffolding 210 substantially or completely degrades from treatment area before coating 220 substantially or completely degrades. In another embodiment, coating 220 delivers a drug to the lumen 240 during degradation of scaffolding 210 and after substantial or complete degradation of scaffolding 210. In yet another embodiment, coating 220 becomes endothelialized in a wall of lumen 240 and delivers a drug after scaffolding 210 has substantially or completely degraded.
  • In one embodiment, the stent includes an anti-proliferative agent that includes, but is not limited to, Everolimus, Rapamycin, and/or derivatives thereof. Everolimus is available under the trade name Certican™, Novartis Pharma AG, Germany. The anti-proliferative agent may be included within the coating material's polymer matrix and/or in the scaffolding's polymer matrix. In one embodiment, the anti-proliferative agent is intermixed or dispersed within the coating material's polymer matrix and/or intermixed or dispersed in the scaffolding's polymer matrix. In certain embodiments, the anti-proliferative agent is included in depots within the coating and/or the scaffolding.
  • The stent may also include an anti-inflammatory agent. Clobetasol is available under the trade name Temovate™, Glaxosmithkline, UK. The anti-inflammatory agent may be included within the coating material's polymer matrix and/or in the scaffolding's polymer matrix. In one embodiment, the anti-inflammatory agent is intermixed or dispersed within the coating material's polymer matrix and/or intermixed or dispersed within the scaffolding's polymer matrix. In certain embodiments, the anti-inflammatory agent is included in depots within the coating and/or the scaffolding.
  • The release of inflammation-inciting by-products into the body from a biodegradable device can occur continuously while the scaffolding is degrading within the body. An anti-inflammatory included within the scaffolding may allow for sustained release of the inflammatory agent throughout the scaffolding's degradation. The drug-delivery stent disclosed herein may include a sustained release of an anti-inflammatory agent from the scaffolding. After the scaffolding absorbs, the coating material remains in the lumen wall.
  • The underlying stent scaffolding is made from a polymeric material that degrades more rapidly than the polymer used to form the coating material. The polymer used to form the scaffolding is faster degrading than the coating material. Any biodegradable polymer may be used to the form the scaffolding and the coating material, as long as the polymer used to make all or substantially all the scaffolding degrades faster than the polymer used to make all or substantially all the coating material. In some embodiments, the scaffolding can be formed of a copolymer that includes two functional groups or units. One of the units tends to increase the degradation rate compared to a homopolymer including the other unit. Thus, glycolide has a faster degradation rate and is more hydrolytically active.
  • In one embodiment, the stent scaffolding is formed of poly(D,L-lactide-co-glycolide), where 10% of the copolymer is D,L-lactide and 90% of the copolymer is glycolide. In another embodiment, the stent scaffolding is formed of poly(L-lactide-co-glycolide), where 10% of the copolymer is D,L-lactide and 90% of the copolymer is glycolide. In this embodiment, any polymer that degrades at a slower rate than poly(D,L-lactide-co-glycolide) may be used to form the coating material. For example; PLLA can be used to form a coating material because PLLA is slower degrading than poly(D,L-lactide-co-glycolide). In another embodiment, the stent scaffolding is formed of poly(D,L-lactide-co-glycolide), where 5-45% of the copolymer is D,L-lactide and 55-95% of the copolymer is glycolide. In yet another embodiment, 1:1 Everolimus and poly(D,L-lactide) is used to form the coating material, which degrades at about 12 months and has the ability to deliver drug for 3 months. Thus, the drug will be delivered even after the scaffolding has degraded, or has been absorbed into the body, or no longer has vascular patency.
  • In one embodiment, the scaffolding is made to degrade rapidly, thereby reducing the risk of a negative reaction to the presence of a degrading stent. Certain embodiments provide for a rapidly degrading scaffolding, one that degrades within 6 months, within 3 months, or more narrowly within 2 months.
  • In one embodiment, the stent scaffolding may be fabricated to include an erodible metal, such as magnesium. Other material may also be used to fabricate the stent scaffolding, so long as all or substantially all of the scaffolding degrades at a faster rate than all or substantially all of the coating material. In one embodiment, the coating material includes Everolimus and poly(D,L-lactide) of a 1:1 ratio, and the scaffolding includes D,L-lactide and glycolide monomers of a 1:9 ratio, or poly(D,L-lactide-co-glycolide).
  • As described above, it is also possible to have a sustained release of an anti-inflammatory agent from the coating material. The anti-inflammatory agent may be included within the coating and is delivered from a surface of the coating. The coating material may be configured to sustain delivery of anti-inflammatory agent throughout the degradation of a stent scaffolding to counteract the inflammatory effect of the degradation of by-products.
  • In one embodiment, an anti-inflammatory agent is included in both the coating and the scaffolding. An anti-inflammatory agent may be delivered from the coating as well as the scaffolding to suppress inflammation of a body lumen during all or a majority of the degradation of the scaffolding.
  • In one embodiment, a first stent is deployed at a treatment area, and a second stent is deployed in at least a portion of the treatment area, or the treatment area is “re-stented”.
  • The first stent includes a bioabsorbable polymeric scaffolding and a coating having a bioabsorbable material on at least a portion of the scaffolding. The degradation rate of all or substantially all of the bioabsorbable polymer of the scaffolding is faster than the degradation rate of all or substantially all of the bioabsorbable material of the coating;
  • The second stent is deployed when the scaffolding of the first stent has at least partially degraded, has substantially degraded, or has completely degraded. Thus, embodiments disclosed herein may prove advantageous to methods for re-stenting a lumen. Certain embodiments provide for a rapidly degrading scaffolding, that degrades within 6 months, within 3 months, or more narrowly within 2 months. Re-stenting is facilitated by rapid degradation of the first stent's scaffolding, enabling a second stent to be implanted in the stented area or treatment area within only a few months after the first stent has been implanted. When the second stent is deployed in the treatment area, the functional lumen diameter is not reduced as is the case when a second stent is deployed at an treatment area of a first stent that has only partially degraded. In the latter case, the reduced functional diameter causes the blood flow to fall significantly and possibly congest the lumen.
  • Depicted in FIG. 3 is a second stent 300 that has been implanted in the same treatment area 310 as a first stent 320. In some embodiments, second stent 300 is implanted in lumen 330 after endothelialization of first stent 320. In some embodiments, second stent 300 is implanted in lumen 330 after a scaffolding (not depicted) of a first stent 320 is at least partially degraded, substantially degraded, or more narrowly, completely degraded in lumen 330. In some embodiments, second stent 300 is deployed in treatment area 310 when scaffolding (not pictured) of the first stent is greater than 50% degraded, greater than 75% degraded, and more narrowly, greater than 95% degraded as known of those skilled in the art.
  • In one embodiment, second stent 300 may be implanted in treatment area 310 after all or substantially all of scaffolding of first stent 320 has is degraded, such that only a coating material 340 of first stent 320 remains in the lumen. In certain embodiments, coating material 320 of first stent 340 continues to deliver drug when second stent 300 is implanted.
  • As discussed above, a drug(s) may be included in the coating or scaffolding of the first stent. Thus, when the second stent is implanted, the first stent may deliver drug from at least a portion of the coating material of the first stent while the second stent is implanted. For example, an anti-inflammatory agent may be included within the coating material of the first stent, such that when the scaffolding of the second stent is implanted, the anti-inflammatory agent continues to deliver drug to prevent inflammation. As mentioned above, the anti-inflammatory agent that is delivered from the coating material of the first stent may also effectively suppress inflammation of a lumen during all or a majority of the degradation of the scaffolding of the first stent.
  • In a further embodiment, an anti-inflammatory drug and/or an anti-proliferative drug is included in the coating and/or the scaffolding of the stent and is designed to have release parameters for drugs included. The second stent may have a biostable or biodegradable scaffolding made from a metal, polymer, or combination thereof. The second stent may or may not include a coating or a drug.
  • The drug mixed or dispersed within a biodegradable scaffolding may be delivered into a lumen at substantially the same, a faster rate, or a slower rate as the scaffolding degrades. In one embodiment, the drug may be incorporated within the scaffolding during fabrication of the stent according to the general skill in the art. For example, an anti-inflammatory agent may be incorporated in the scaffolding, and configured to be delivered through the coating material to treat inflamed portions of lumens.
  • Moreover, the properties of the coating, such as thickness and porosity, may influence the rate of release of the drug(s) from the stent. Some embodiments may include controlling the release rate of the drug by modifying the properties of the coating.
  • In one embodiment, the stent includes a scaffolding and depots having drug. As used herein, the coating described above includes depots. In one embodiment, one or more drugs may be contained within at least one depot or cavity on at least a portion of a surface of the scaffolding. The drug in the depot may be pure or substantially pure drug. Alternatively, the drug in the depot may be mixed or dispersed in a polymer matrix, which degrades at a faster rate than the scaffolding. Thus, the scaffolding may degrade first, while the drug/polymer mixture within the depots continues to deliver drug long after the scaffolding has degraded. Numerous embodiments of a stent with depots configured to hold a drug are possible. Depots may be placed at one or more arbitrary locations on a stent. The greater inflammation may arise from a larger concentration of degradation products closer to the center of the stent than the ends of the stent. Thus, the center of the lesion may require more anti-inflammatory agent than the ends of the lesion. Alternatively, the ends of the lesion may be more inflamed due to mechanical stresses causing irritation or injury to the ends of the lesion. Thus, a stent may include depots or more depots in regions of a stent adjacent portions of a lesion having more inflammation.
  • The anti-proliferative agent can be a natural proteineous agent such as a cytotoxin or a synthetic molecule. Preferably, the active agents include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich 1001 West Saint Paul Avenue, Milwaukee, Wis. 53233; or COSMEGEN available from Merck) (synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I1, actinomycin X1, and actinomycin C1), all taxoids such as taxols, docetaxel, and paclitaxel, paclitaxel derivatives, all olimus drugs such as macrolide antibiotics, rapamycin, Everolimus, structural derivatives and functional analogues of rapamycin, structural derivatives and functional analogues of Everolimus, FKBP-12 mediated mTOR inhibitors, biolimus, perfenidone, prodrugs thereof, co-drugs thereof, and combinations thereof. Representative rapamycin derivatives include 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, or 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578 manufactured by Abbot Laboratories, Abbot Park, Ill.), prodrugs thereof, co-drugs thereof, and combinations thereof.
  • Any drugs having anti-inflammatory effects can be used in the present invention. The anti-inflammatory drug can be a steroidal anti-inflammatory agent, a nonsteroidal anti-inflammatory agent, or a combination thereof. In some embodiments, anti-inflammatory drugs include, but are not limited to, alclofenac, alclometasone dipropionate, algestone acetonide, alpha amylase, amcinafal, amcinafide, amfenac sodium, amiprilose hydrochloride, anakinra, anirolac, anitrazafen, apazone, balsalazide disodium, bendazac, benoxaprofen, benzydamine hydrochloride, bromelains, broperamole, budesonide, carprofen, cicloprofen, cintazone, cliprofen, Clobetasol propionate, clobetasone butyrate, clopirac, cloticasone propionate, cormethasone acetate, cortodoxone, deflazacort, desonide, desoximetasone, dexamethasone dipropionate, diclofenac potassium, diclofenac sodium, diflorasone diacetate, diflumidone sodium, diflunisal, difluprednate, diftalone, dimethyl sulfoxide, drocinonide, endrysone, enlimomab, enolicam sodium, epirizole, etodolac, etofenamate, felbinac, fenamole, fenbufen, fenclofenac, fenclorac, fendosal, fenpipalone, fentiazac, flazalone, fluazacort, flufenamic acid, flumizole, flunisolide acetate, flunixin, flunixin meglumine, fluocortin butyl, fluorometholone acetate, fluquazone, flurbiprofen, fluretofen, fluticasone propionate, fuiraprofen, furobufen, halcinonide, halobetasol propionate, halopredone acetate, ibufenac, ibuprofen, ibuprofen aluminum, ibuprofen piconol, ilonidap, indomethacin, indomethacin sodium, indoprofen, indoxole, intrazole, isoflupredone acetate, isoxepac, isoxicam, ketoprofen, lofemizole hydrochloride, lomoxicam, loteprednol etabonate, meclofenamate sodium, meclofenamic acid, meclorisone dibutyrate, mefenamic acid, mesalamine, meseclazone, methylprednisolone suleptanate, momiflumate, nabumetone, naproxen, naproxen sodium, naproxol, nimazone, olsalazine sodium, orgotein, orpanoxin, oxaprozin, oxyphenbutazone, paranyline hydrochloride, pentosan polysulfate sodium, phenbutazone sodium glycerate, pirfenidone, piroxicam, piroxicam cinnamate, piroxicam olamine, pirprofen, prednazate, prifelone, prodolic acid, proquazone, proxazole, proxazole citrate, rimexolone, romazarit, salcolex, salnacedin, salsalate, sanguinarium chloride, seclazone, sermetacin, sudoxicam, sulindac, suprofen, talmetacin, talniflumate, talosalate, tebufelone, tenidap, tenidap sodium, tenoxicam, tesicam, tesimide, tetrydamine, tiopinac, tixocortol pivalate, tolmetin, tolmetin sodium, triclonide, triflumidate, zidometacin, zomepirac sodium, aspirin (acetylsalicylic acid), salicylic acid, corticosteroids, glucocorticoids, tacrolimus, pimecorlimus, prodrugs thereof, co-drugs thereof, and combinations thereof.
  • The relative amount of the anti-proliferative agent and/or anti-inflammatory agent in the stent can be determined by the lumen to be treated. For example, where Everolimus is used as the anti-proliferative agent and Clobetasol is used as the anti-inflammatory agent, the relative amount of Everolimus and Clobetasol can be varied for different types of lesions, that is, the relative amount of Everolimus can be higher for more proliferative lesions, and on the other hand, the relative amount of Clobetasol can be higher for more inflammatory lesions.
  • In some embodiments, other agents can be used in combination with the anti-proliferative agent and the anti-inflammatory agents. These bioactive agents can be any agent which is a therapeutic, prophylactic, or diagnostic agent. These agents can also have anti-proliferative and/or anti-inflammmatory properties or can have other properties such as antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic, antioxidant as well as cystostatic agents. Examples of suitable therapeutic and prophylactic agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes. Some other examples of other bioactive agents include antibodies, receptor ligands, enzymes, adhesion peptides, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy. Examples of antineoplastics and/or antimitotics include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, thrombin inhibitors such as Angiomax a (Biogen, Inc., Cambridge, Mass.), calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), nitric oxide or nitric oxide donors, super oxide dismutases, super oxide dismutase mimetic, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), estradiol, anticancer agents, dietary supplements such as various vitamins, and a combination thereof. Examples of such cytostatic substance include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J.). An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, and genetically engineered epithelial cells. The foregoing substances are listed by way of example and are not meant to be limiting. Other active agents which are currently available or that may be developed in the future are equally applicable.
  • Representative examples of polymers that may be used to fabricate the scaffolding, the coating, or to provide a drug delivery particle with the anti-proliferative drug and/or anti-inflammatory drug include, but are not limited to, poly(N-acetylglucosamine) (Chitin), Chitosan, poly(3-hydroxyvalerate), poly(lactide-co-glycolide), poly(3-hydroxybutyrate), poly(4-hydroxybutyrate), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolide), poly(L-lactic acid), poly(L-lactide), poly(D,L-lactic acid), poly(D,L-lactide), poly(L-lactide-co-D,L-lactide), poly(caprolactone), poly(L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone), poly(glycolide-co-caprolactone), poly(trimethylene carbonate), polyester amide, poly(glycolic acid-co-trimethylene carbonate), co-poly(ether-esters) (e.g. PEO/PLA), polyphosphazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers other than polyacrylates, vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene halides (such as polyvinylidene chloride), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), acrylonitrile-styrene copolymers, ABS resins, polyamides (such as Nylon 66 and polycaprolactam), polycarbonates, polyoxymethylenes, polyimides, polyethers, polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose. Additional representative examples of polymers that may be especially well suited for use in fabricating embodiments of stents disclosed herein include ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL), poly(butyl methacrylate), poly(vinylidene fluoride-co-hexafluoropropene) (e.g., SOLEF 21508, available from Solvay Solexis PVDF, Thorofare, N.J.), polyvinylidene fluoride (otherwise known as KYNAR, available from ATOFINA Chemicals, Philadelphia, Pa.), ethylene-vinyl acetate copolymers, poly(vinyl acetate), styrene-isobutylene-styrene triblock copolymers, and polyethylene glycol.
  • The coating material described herein can be formed by spray coating or any other coating process available in the art. Generally, the coating material involves dissolving or suspending the coating material, or one or more components thereof, in a solvent or solvent mixture to form a solution, suspension, or dispersion of the coating material or one or more components thereof, applying the solution or suspension to an implantable stent, and removing the solvent or solvent mixture to form a coating or a layer of coating. As used herein, the term “solvent” refers to a liquid substance or coating material that is compatible with the polymer and is capable of dissolving or suspending the polymeric coating material or one or more components thereof at a desired concentration.
  • In some embodiments, the coating can include a primer layer and/or topcoat layers or sub-layers. The primer layer will be beneath the drug/therapeutic substance layer and the topcoat layer above it. Both the primer layer and the topcoat layer can be without any drugs/therapeutic substances. In some embodiments, some drug may incidentally migrate into the primer layer or region. The topcoat layer reduces the rate of release of the drug and/or provides for bio-beneficial properties.
  • Although embodiments disclosed herein are focused on stents, the embodiments may be applied to any implantable medical device that has a coating and a substrate.
  • The stent or drug-delivery system disclosed herein can be used to treat or prevent a disorder including but not limited to thrombosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, restenosis and progression of atherosclerosis in patient subsets including type I diabetics, type II diabetics, metabolic syndrome and syndrome X, vulnerable lesions including those with thin-capped fibroatheromatous lesions, systemic infections including gingivitis, hellobacteria, and cytomegalovirus, and combinations thereof.
  • A stent having the above-described coating material is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in bile ducts, esophagus, trachea/bronchi and other biological passageways. A stent having the above-described coating material is particularly useful for treating occluded regions of body lumens caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, thrombosis, and restenosis. Stents may be placed in a wide array of body lumens, both arteries and veins. Representative examples of sites include the iliac, renal, and coronary arteries.
  • While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects.

Claims (32)

  1. 1. A stent comprising:
    a bioabsorbable polymeric scaffolding; and
    a coating comprising a bioabsorbable material on at least a portion of the scaffolding, wherein the degradation rate of all or substantially all of the bioabsorbable polymer of the scaffolding is faster than the degradation rate of all or substantially all of the bioabsorbable material of the coating.
  2. 2. The stent according to claim 1, wherein the stent includes an anti-proliferative agent, an anti-inflammatory agent, or a mixture thereof.
  3. 3. The stent according to claim 2, wherein the anti-proliferative agent is selected from the group consisting of Everolimus, Rapamycin, and/or derivatives thereof.
  4. 4. The stent according to claim 2, wherein the anti-inflammatory agent is Clobetasol.
  5. 5. The stent according to claim 1, wherein the coating material comprises Everolimus and poly(D,L-lactide) of a 1:1 ratio, and the scaffolding comprises D,L-lactide and glycolide monomers of a 1:9 ratio.
  6. 6. A method treating a body lumen, the method comprising:
    providing a stent comprising a scaffolding that degrades at a faster rate than a coating on the scaffolding; and
    deploying the stent at a treatment area in a body lumen.
  7. 7. The method according to claim 6, wherein the stent includes an anti-proliferative agent, an anti-inflammatory agent, or a mixture thereof.
  8. 8. The method according to claim 6, wherein an anti-inflammatory agent is mixed or dispersed within the scaffolding.
  9. 9. The method according to claim 6, wherein an anti-inflammatory agent and the anti-proliferative agent is delivered from at least a portion of the coating.
  10. 10. The method according to claim 6, wherein an anti-inflammatory agent is delivered from the scaffolding and suppresses inflammation of the lumen during all or a majority of the degradation of the scaffolding.
  11. 11. The method according to claim 6, wherein the coating in the stent comprises Everolimus and poly(D,L-lactide) of a 1:1 ratio, and the scaffolding comprises D,L-lactide and glycolide monomers of a 1:9 ratio.
  12. 12. The method according to claim 6, wherein the stent includes Everolimus, Rapamycin, and/or derivatives thereof.
  13. 13. The method according to claim 6, wherein the stent includes Clobetasol.
  14. 14. The method according to claim 6, wherein upon deployment of the stent in the treatment area, the scaffolding substantially or completely degrades from the treatment area before the coating substantially or completely degrades.
  15. 15. The method according to claim 6, wherein the coating delivers a drug to the lumen during degradation of the scaffolding and after substantial or complete degradation of the scaffolding.
  16. 16. The method according to claim 6, wherein the coating becomes endothelialized in a wall of the lumen and delivers a drug after the scaffolding has substantially or completely degraded.
  17. 17. A method of treating a body lumen, the method comprising:
    deploying a first stent at a treatment area, wherein the first stent includes a bioabsorbable polymeric scaffolding and a coating having a bioabsorbable material on at least a portion of the scaffolding, and wherein the degradation rate of all or substantially all of the bioabsorbable polymer of the scaffolding is faster than the degradation rate of all or substantially all of the bioabsorbable material of the coating; and
    deploying a second stent in at least a portion of the treatment area.
  18. 18. The method according to claim 17, wherein an anti-inflammatory agent is mixed or dispersed within the scaffolding.
  19. 19. The method according to claim 17, wherein an anti-inflammatory agent is delivered from at least a portion of the coating material of the first stent, wherein the coating material comprises an anti-proliferative agent.
  20. 20. The method according to claim 17, wherein an anti-inflammatory agent is delivered from the scaffolding of the first stent and suppresses inflammation of the body lumen during substantial or complete degradation of the scaffolding.
  21. 21. The method according to claim 17, wherein the stent includes an anti-proliferative agent.
  22. 22. The method according to claim 21, wherein the anti-proliferative agent in the first stent is Everolimus, Rapamycin, and/or derivatives thereof.
  23. 23. The method according to claim 17, wherein the first stent includes an anti-inflammatory agent.
  24. 24. The method according to claim 23, wherein the anti-inflammatory agent in the first stent is Clobetasol.
  25. 25. The method according to claim 17, wherein the coating material in the first stent comprises Everolimus and poly(D,L-lactide) of a 1:1 ratio, and the scaffolding comprises D,L-lactide and glycolide monomers of a 1:9 ratio.
  26. 26. The method according to claim 17, wherein the second stent is deployed when the scaffolding has substantially or completely degraded.
  27. 27. The method according to claim 17, wherein the coating material of the first stent is capable of at least partially eluting a drug when the second stent is deployed.
  28. 28. The method according to claim 17, wherein the first stent includes Everolimus, Rapamycin, and/or derivatives thereof.
  29. 29. The method according to claim 17, wherein the first stent includes Clobetasol.
  30. 30. The method according to claim 17, wherein upon deployment of the stent in the treatment area, the scaffolding substantially or completely degrades from the treatment area before the coating substantially or completely degrades.
  31. 31. The method according to claim 17, wherein the coating delivers a drug to the lumen during degradation of the scaffolding and after substantial or complete degradation of the scaffolding.
  32. 32. The method according to claim 17, wherein the coating becomes endothelialized in a wall of the lumen and delivers a drug after the scaffolding has substantially or completely degraded.
US11582706 2006-10-17 2006-10-17 Drug delivery after biodegradation of the stent scaffolding Abandoned US20080091262A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11582706 US20080091262A1 (en) 2006-10-17 2006-10-17 Drug delivery after biodegradation of the stent scaffolding

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11582706 US20080091262A1 (en) 2006-10-17 2006-10-17 Drug delivery after biodegradation of the stent scaffolding
US11823703 US8016879B2 (en) 2006-08-01 2007-06-27 Drug delivery after biodegradation of the stent scaffolding
PCT/US2007/016772 WO2008016528A3 (en) 2006-08-01 2007-07-25 Drug delivery after biodegradation of the stent scaffolding
US13086308 US8398706B2 (en) 2006-10-17 2011-04-13 Drug delivery after biodegradation of the stent scaffolding
US13185370 US8469968B2 (en) 2006-08-01 2011-07-18 Methods of treatment with drug delivery after biodegradation of the stent scaffolding
US13925750 US8876890B2 (en) 2006-08-01 2013-06-24 Methods of treatment with biodegradation of a stent scaffolding
US14531744 US9345816B2 (en) 2006-08-01 2014-11-03 Methods of treatment with drug delivery after biodegradation of the stent scaffolding

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11823703 Continuation-In-Part US8016879B2 (en) 2006-08-01 2007-06-27 Drug delivery after biodegradation of the stent scaffolding
US13086308 Division US8398706B2 (en) 2006-10-17 2011-04-13 Drug delivery after biodegradation of the stent scaffolding

Publications (1)

Publication Number Publication Date
US20080091262A1 true true US20080091262A1 (en) 2008-04-17

Family

ID=39303985

Family Applications (2)

Application Number Title Priority Date Filing Date
US11582706 Abandoned US20080091262A1 (en) 2006-10-17 2006-10-17 Drug delivery after biodegradation of the stent scaffolding
US13086308 Active 2026-12-05 US8398706B2 (en) 2006-10-17 2011-04-13 Drug delivery after biodegradation of the stent scaffolding

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13086308 Active 2026-12-05 US8398706B2 (en) 2006-10-17 2011-04-13 Drug delivery after biodegradation of the stent scaffolding

Country Status (1)

Country Link
US (2) US20080091262A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090110713A1 (en) * 2007-10-31 2009-04-30 Florencia Lim Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices
US20090291111A1 (en) * 2008-05-21 2009-11-26 Florencia Lim Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
US20100070013A1 (en) * 2008-09-18 2010-03-18 Medtronic Vascular, Inc. Medical Device With Microsphere Drug Delivery System
US20100298952A1 (en) * 2009-05-20 2010-11-25 Arsenal Medical Medical implant
US20110190875A1 (en) * 2006-10-17 2011-08-04 Advanced Cardiovascular Systems, Inc. Drug Delivery After Biodegradation Of The Stent Scaffolding
US20130138219A1 (en) * 2011-11-28 2013-05-30 Cook Medical Technologies Llc Biodegradable stents having one or more coverings
US8469968B2 (en) 2006-08-01 2013-06-25 Abbott Cardiovascular Systems Inc. Methods of treatment with drug delivery after biodegradation of the stent scaffolding
US8540765B2 (en) 2009-05-20 2013-09-24 480 Biomedical, Inc. Medical implant
US20140242144A1 (en) * 2012-02-10 2014-08-28 Abbott Cardiovascular Systems Inc. Drug eluting scaffold for kidney-related disease
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
US9090745B2 (en) 2007-06-29 2015-07-28 Abbott Cardiovascular Systems Inc. Biodegradable triblock copolymers for implantable devices
WO2015160501A1 (en) 2014-04-18 2015-10-22 Auburn University Particulate vaccine formulations for inducing innate and adaptive immunity
US20150359943A1 (en) * 2001-06-27 2015-12-17 Abbott Cardiovascular Systems Inc. Pdlla stent coating
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
WO2017049284A1 (en) * 2015-09-17 2017-03-23 Hollister Incorporated Scaffold-based wound care delivery system and method
US10076591B2 (en) 2010-03-31 2018-09-18 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device

Citations (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321711A (en) * 1978-10-18 1982-03-30 Sumitomo Electric Industries, Ltd. Vascular prosthesis
US4633873A (en) * 1984-04-26 1987-01-06 American Cyanamid Company Surgical repair mesh
US4656083A (en) * 1983-08-01 1987-04-07 Washington Research Foundation Plasma gas discharge treatment for improving the biocompatibility of biomaterials
US4718907A (en) * 1985-06-20 1988-01-12 Atrium Medical Corporation Vascular prosthesis having fluorinated coating with varying F/C ratio
US4722335A (en) * 1986-10-20 1988-02-02 Vilasi Joseph A Expandable endotracheal tube
US4723549A (en) * 1986-09-18 1988-02-09 Wholey Mark H Method and apparatus for dilating blood vessels
US4732152A (en) * 1984-12-05 1988-03-22 Medinvent S.A. Device for implantation and a method of implantation in a vessel using such device
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4740207A (en) * 1986-09-10 1988-04-26 Kreamer Jeffry W Intralumenal graft
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4816339A (en) * 1987-04-28 1989-03-28 Baxter International Inc. Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation
US4818559A (en) * 1985-08-08 1989-04-04 Sumitomo Chemical Company, Limited Method for producing endosseous implants
US4902289A (en) * 1982-04-19 1990-02-20 Massachusetts Institute Of Technology Multilayer bioreplaceable blood vessel prosthesis
US4994298A (en) * 1988-06-07 1991-02-19 Biogold Inc. Method of making a biocompatible prosthesis
US5084065A (en) * 1989-07-10 1992-01-28 Corvita Corporation Reinforced graft assembly
US5085629A (en) * 1988-10-06 1992-02-04 Medical Engineering Corporation Biodegradable stent
US5100429A (en) * 1989-04-28 1992-03-31 C. R. Bard, Inc. Endovascular stent and delivery system
US5104410A (en) * 1990-10-22 1992-04-14 Intermedics Orthopedics, Inc Surgical implant having multiple layers of sintered porous coating and method
US5108417A (en) * 1990-09-14 1992-04-28 Interface Biomedical Laboratories Corp. Anti-turbulent, anti-thrombogenic intravascular stent
US5108755A (en) * 1989-04-27 1992-04-28 Sri International Biodegradable composites for internal medical use
US5192311A (en) * 1988-04-25 1993-03-09 Angeion Corporation Medical implant and method of making
US5197977A (en) * 1984-01-30 1993-03-30 Meadox Medicals, Inc. Drug delivery collagen-impregnated synthetic vascular graft
US5279594A (en) * 1990-05-23 1994-01-18 Jackson Richard R Intubation devices with local anesthetic effect for medical use
US5282860A (en) * 1991-10-16 1994-02-01 Olympus Optical Co., Ltd. Stent tube for medical use
US5289831A (en) * 1989-03-09 1994-03-01 Vance Products Incorporated Surface-treated stent, catheter, cannula, and the like
US5290271A (en) * 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
US5306286A (en) * 1987-06-25 1994-04-26 Duke University Absorbable stent
US5306294A (en) * 1992-08-05 1994-04-26 Ultrasonic Sensing And Monitoring Systems, Inc. Stent construction of rolled configuration
US5383925A (en) * 1992-09-14 1995-01-24 Meadox Medicals, Inc. Three-dimensional braided soft tissue prosthesis
US5385580A (en) * 1990-08-28 1995-01-31 Meadox Medicals, Inc. Self-supporting woven vascular graft
US5389106A (en) * 1993-10-29 1995-02-14 Numed, Inc. Impermeable expandable intravascular stent
US5399666A (en) * 1994-04-21 1995-03-21 E. I. Du Pont De Nemours And Company Easily degradable star-block copolymers
US5502158A (en) * 1988-08-08 1996-03-26 Ecopol, Llc Degradable polymer composition
US5591607A (en) * 1994-03-18 1997-01-07 Lynx Therapeutics, Inc. Oligonucleotide N3→P5' phosphoramidates: triplex DNA formation
US5591199A (en) * 1995-06-07 1997-01-07 Porter; Christopher H. Curable fiber composite stent and delivery system
US5593403A (en) * 1994-09-14 1997-01-14 Scimed Life Systems Inc. Method for modifying a stent in an implanted site
US5593434A (en) * 1992-01-31 1997-01-14 Advanced Cardiovascular Systems, Inc. Stent capable of attachment within a body lumen
US5599301A (en) * 1993-11-22 1997-02-04 Advanced Cardiovascular Systems, Inc. Motor control system for an automatic catheter inflation system
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5607467A (en) * 1990-09-14 1997-03-04 Froix; Michael Expandable polymeric stent with memory and delivery apparatus and method
US5607442A (en) * 1995-11-13 1997-03-04 Isostent, Inc. Stent with improved radiopacity and appearance characteristics
US5618299A (en) * 1993-04-23 1997-04-08 Advanced Cardiovascular Systems, Inc. Ratcheting stent
US5707385A (en) * 1994-11-16 1998-01-13 Advanced Cardiovascular Systems, Inc. Drug loaded elastic membrane and method for delivery
US5711763A (en) * 1991-02-20 1998-01-27 Tdk Corporation Composite biological implant of a ceramic material in a metal substrate
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5726297A (en) * 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5725549A (en) * 1994-03-11 1998-03-10 Advanced Cardiovascular Systems, Inc. Coiled stent with locking ends
US5728751A (en) * 1996-11-25 1998-03-17 Meadox Medicals, Inc. Bonding bio-active materials to substrate surfaces
US5733925A (en) * 1993-01-28 1998-03-31 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5733326A (en) * 1996-05-28 1998-03-31 Cordis Corporation Composite material endoprosthesis
US5733330A (en) * 1997-01-13 1998-03-31 Advanced Cardiovascular Systems, Inc. Balloon-expandable, crush-resistant locking stent
US5733564A (en) * 1993-04-14 1998-03-31 Leiras Oy Method of treating endo-osteal materials with a bisphosphonate solution
US5741881A (en) * 1996-11-25 1998-04-21 Meadox Medicals, Inc. Process for preparing covalently bound-heparin containing polyurethane-peo-heparin coating compositions
US5855612A (en) * 1995-05-12 1999-01-05 Ohta Inc. Biocompatible titanium implant
US5855618A (en) * 1996-09-13 1999-01-05 Meadox Medicals, Inc. Polyurethanes grafted with polyethylene oxide chains containing covalently bonded heparin
US5858746A (en) * 1992-04-20 1999-01-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5865814A (en) * 1995-06-07 1999-02-02 Medtronic, Inc. Blood contacting medical device and method
US5868781A (en) * 1996-10-22 1999-02-09 Scimed Life Systems, Inc. Locking stent
US5874109A (en) * 1994-07-27 1999-02-23 The Trustees Of The University Of Pennsylvania Incorporation of biological molecules into bioactive glasses
US5874101A (en) * 1997-04-14 1999-02-23 Usbiomaterials Corp. Bioactive-gel compositions and methods
US5874165A (en) * 1996-06-03 1999-02-23 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto polymeric subtrates
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US5877263A (en) * 1996-11-25 1999-03-02 Meadox Medicals, Inc. Process for preparing polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents
US5876743A (en) * 1995-03-21 1999-03-02 Den-Mat Corporation Biocompatible adhesion in tissue repair
US5879713A (en) * 1994-10-12 1999-03-09 Focal, Inc. Targeted delivery via biodegradable polymers
US5888533A (en) * 1995-10-27 1999-03-30 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5891192A (en) * 1997-05-22 1999-04-06 The Regents Of The University Of California Ion-implanted protein-coated intralumenal implants
US6010445A (en) * 1997-09-11 2000-01-04 Implant Sciences Corporation Radioactive medical device and process
US6015541A (en) * 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
US6042875A (en) * 1997-04-30 2000-03-28 Schneider (Usa) Inc. Drug-releasing coatings for medical devices
US6171609B1 (en) * 1995-02-15 2001-01-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6174330B1 (en) * 1997-08-01 2001-01-16 Schneider (Usa) Inc Bioabsorbable marker having radiopaque constituents
US6177523B1 (en) * 1999-07-14 2001-01-23 Cardiotech International, Inc. Functionalized polyurethanes
US6183505B1 (en) * 1999-03-11 2001-02-06 Medtronic Ave, Inc. Method of stent retention to a delivery catheter balloon-braided retainers
US6187045B1 (en) * 1999-02-10 2001-02-13 Thomas K. Fehring Enhanced biocompatible implants and alloys
US20020002399A1 (en) * 1999-12-22 2002-01-03 Huxel Shawn Thayer Removable stent for body lumens
US20020004101A1 (en) * 1995-04-19 2002-01-10 Schneider (Usa) Inc. Drug coating with topcoat
US20020004060A1 (en) * 1997-07-18 2002-01-10 Bernd Heublein Metallic implant which is degradable in vivo
US6511748B1 (en) * 1998-01-06 2003-01-28 Aderans Research Institute, Inc. Bioabsorbable fibers and reinforced composites produced therefrom
US6517888B1 (en) * 2000-11-28 2003-02-11 Scimed Life Systems, Inc. Method for manufacturing a medical device having a coated portion by laser ablation
US20030033001A1 (en) * 2001-02-27 2003-02-13 Keiji Igaki Stent holding member and stent feeding system
US20030039689A1 (en) * 2001-04-26 2003-02-27 Jianbing Chen Polymer-based, sustained release drug delivery system
US6527801B1 (en) * 2000-04-13 2003-03-04 Advanced Cardiovascular Systems, Inc. Biodegradable drug delivery material for stent
US6537589B1 (en) * 2000-04-03 2003-03-25 Kyung Won Medical Co., Ltd. Calcium phosphate artificial bone as osteoconductive and biodegradable bone substitute material
US6676697B1 (en) * 1996-09-19 2004-01-13 Medinol Ltd. Stent with variable features to optimize support and method of making such stent
US6679980B1 (en) * 2001-06-13 2004-01-20 Advanced Cardiovascular Systems, Inc. Apparatus for electropolishing a stent
US6689375B1 (en) * 1999-11-09 2004-02-10 Coripharm Medizinprodukte Gmbh & Co. Kg Resorbable bone implant material and method for producing the same
US20040030380A1 (en) * 2002-04-24 2004-02-12 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6695920B1 (en) * 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US20040039441A1 (en) * 2002-05-20 2004-02-26 Rowland Stephen Maxwell Drug eluting implantable medical device
US6706273B1 (en) * 1999-08-14 2004-03-16 Ivoclar Vivadent Ag Composition for implantation into the human and animal body
US6709379B1 (en) * 1998-11-02 2004-03-23 Alcove Surfaces Gmbh Implant with cavities containing therapeutic agents
US6846323B2 (en) * 2003-05-15 2005-01-25 Advanced Cardiovascular Systems, Inc. Intravascular stent
US20050033412A1 (en) * 2000-09-28 2005-02-10 Wu Steven Z. Method of making an implantable medical device

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006792A1 (en) 1991-10-04 1993-04-15 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
WO1994021196A3 (en) * 1993-03-18 1995-02-16 Bard Inc C R Endovascular stents
US6419945B1 (en) * 1996-01-17 2002-07-16 Cambridge Scientific, Inc. Buffered resorbable internal fixation devices and methods for making material therefore
US20050019404A1 (en) 2003-06-30 2005-01-27 Hsing-Wen Sung Drug-eluting biodegradable stent
WO1998056312A1 (en) 1997-06-13 1998-12-17 Scimed Life Systems, Inc. Stents having multiple layers of biodegradable polymeric composition
DE69935716T2 (en) * 1998-05-05 2007-08-16 Boston Scientific Ltd., St. Michael Stent with smooth end
US6368346B1 (en) * 1999-06-03 2002-04-09 American Medical Systems, Inc. Bioresorbable stent
US6338739B1 (en) * 1999-12-22 2002-01-15 Ethicon, Inc. Biodegradable stent
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
US20040220660A1 (en) * 2001-02-05 2004-11-04 Shanley John F. Bioresorbable stent with beneficial agent reservoirs
DE10150995A1 (en) 2001-10-08 2003-04-10 Biotronik Mess & Therapieg Implant e.g. a stent, comprises a decomposable substance which allows contact between the cell proliferation inhibitor and the stent surroundings only after a specified time
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
EP1635734A2 (en) * 2003-06-09 2006-03-22 MacroPore Biosurgery, Inc. Helical endoluminal stent and related methods
US7435256B2 (en) * 2003-11-06 2008-10-14 Boston Scientific Scimed, Inc. Method and apparatus for controlled delivery of active substance
CA2545136A1 (en) * 2003-11-07 2005-05-26 Gp Medical, Inc. Drug-eluting biodegradable stent
US7785615B2 (en) * 2004-05-28 2010-08-31 Cordis Corporation Biodegradable medical implant with encapsulated buffering agent
US8518100B2 (en) * 2005-12-19 2013-08-27 Advanced Cardiovascular Systems, Inc. Drug eluting stent for the treatment of dialysis graft stenoses
US8394488B2 (en) * 2006-10-06 2013-03-12 Cordis Corporation Bioabsorbable device having composite structure for accelerating degradation
US20080091262A1 (en) * 2006-10-17 2008-04-17 Gale David C Drug delivery after biodegradation of the stent scaffolding

Patent Citations (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321711A (en) * 1978-10-18 1982-03-30 Sumitomo Electric Industries, Ltd. Vascular prosthesis
US4902289A (en) * 1982-04-19 1990-02-20 Massachusetts Institute Of Technology Multilayer bioreplaceable blood vessel prosthesis
US4656083A (en) * 1983-08-01 1987-04-07 Washington Research Foundation Plasma gas discharge treatment for improving the biocompatibility of biomaterials
US5197977A (en) * 1984-01-30 1993-03-30 Meadox Medicals, Inc. Drug delivery collagen-impregnated synthetic vascular graft
US4633873A (en) * 1984-04-26 1987-01-06 American Cyanamid Company Surgical repair mesh
US4732152A (en) * 1984-12-05 1988-03-22 Medinvent S.A. Device for implantation and a method of implantation in a vessel using such device
US4718907A (en) * 1985-06-20 1988-01-12 Atrium Medical Corporation Vascular prosthesis having fluorinated coating with varying F/C ratio
US4818559A (en) * 1985-08-08 1989-04-04 Sumitomo Chemical Company, Limited Method for producing endosseous implants
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4739762A (en) * 1985-11-07 1988-04-26 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4733665B1 (en) * 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4739762B1 (en) * 1985-11-07 1998-10-27 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4740207A (en) * 1986-09-10 1988-04-26 Kreamer Jeffry W Intralumenal graft
US4723549A (en) * 1986-09-18 1988-02-09 Wholey Mark H Method and apparatus for dilating blood vessels
US4722335A (en) * 1986-10-20 1988-02-02 Vilasi Joseph A Expandable endotracheal tube
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4816339A (en) * 1987-04-28 1989-03-28 Baxter International Inc. Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation
US5306286A (en) * 1987-06-25 1994-04-26 Duke University Absorbable stent
US5192311A (en) * 1988-04-25 1993-03-09 Angeion Corporation Medical implant and method of making
US4994298A (en) * 1988-06-07 1991-02-19 Biogold Inc. Method of making a biocompatible prosthesis
US5502158A (en) * 1988-08-08 1996-03-26 Ecopol, Llc Degradable polymer composition
US5085629A (en) * 1988-10-06 1992-02-04 Medical Engineering Corporation Biodegradable stent
US5289831A (en) * 1989-03-09 1994-03-01 Vance Products Incorporated Surface-treated stent, catheter, cannula, and the like
US5108755A (en) * 1989-04-27 1992-04-28 Sri International Biodegradable composites for internal medical use
US5100429A (en) * 1989-04-28 1992-03-31 C. R. Bard, Inc. Endovascular stent and delivery system
US5084065A (en) * 1989-07-10 1992-01-28 Corvita Corporation Reinforced graft assembly
US5290271A (en) * 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
US5279594A (en) * 1990-05-23 1994-01-18 Jackson Richard R Intubation devices with local anesthetic effect for medical use
US5385580A (en) * 1990-08-28 1995-01-31 Meadox Medicals, Inc. Self-supporting woven vascular graft
US5607467A (en) * 1990-09-14 1997-03-04 Froix; Michael Expandable polymeric stent with memory and delivery apparatus and method
US5108417A (en) * 1990-09-14 1992-04-28 Interface Biomedical Laboratories Corp. Anti-turbulent, anti-thrombogenic intravascular stent
US5104410A (en) * 1990-10-22 1992-04-14 Intermedics Orthopedics, Inc Surgical implant having multiple layers of sintered porous coating and method
US5711763A (en) * 1991-02-20 1998-01-27 Tdk Corporation Composite biological implant of a ceramic material in a metal substrate
US5282860A (en) * 1991-10-16 1994-02-01 Olympus Optical Co., Ltd. Stent tube for medical use
US5593434A (en) * 1992-01-31 1997-01-14 Advanced Cardiovascular Systems, Inc. Stent capable of attachment within a body lumen
US5858746A (en) * 1992-04-20 1999-01-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5306294A (en) * 1992-08-05 1994-04-26 Ultrasonic Sensing And Monitoring Systems, Inc. Stent construction of rolled configuration
US5383925A (en) * 1992-09-14 1995-01-24 Meadox Medicals, Inc. Three-dimensional braided soft tissue prosthesis
US5733925A (en) * 1993-01-28 1998-03-31 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5733564A (en) * 1993-04-14 1998-03-31 Leiras Oy Method of treating endo-osteal materials with a bisphosphonate solution
US5618299A (en) * 1993-04-23 1997-04-08 Advanced Cardiovascular Systems, Inc. Ratcheting stent
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5389106A (en) * 1993-10-29 1995-02-14 Numed, Inc. Impermeable expandable intravascular stent
US5599301A (en) * 1993-11-22 1997-02-04 Advanced Cardiovascular Systems, Inc. Motor control system for an automatic catheter inflation system
US5725549A (en) * 1994-03-11 1998-03-10 Advanced Cardiovascular Systems, Inc. Coiled stent with locking ends
US5591607A (en) * 1994-03-18 1997-01-07 Lynx Therapeutics, Inc. Oligonucleotide N3→P5' phosphoramidates: triplex DNA formation
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) * 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US6169170B1 (en) * 1994-03-18 2001-01-02 Lynx Therapeutics, Inc. Oligonucleotide N3′→N5′Phosphoramidate Duplexes
US5399666A (en) * 1994-04-21 1995-03-21 E. I. Du Pont De Nemours And Company Easily degradable star-block copolymers
US5874109A (en) * 1994-07-27 1999-02-23 The Trustees Of The University Of Pennsylvania Incorporation of biological molecules into bioactive glasses
US5593403A (en) * 1994-09-14 1997-01-14 Scimed Life Systems Inc. Method for modifying a stent in an implanted site
US5879713A (en) * 1994-10-12 1999-03-09 Focal, Inc. Targeted delivery via biodegradable polymers
US5707385A (en) * 1994-11-16 1998-01-13 Advanced Cardiovascular Systems, Inc. Drug loaded elastic membrane and method for delivery
US6171609B1 (en) * 1995-02-15 2001-01-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5876743A (en) * 1995-03-21 1999-03-02 Den-Mat Corporation Biocompatible adhesion in tissue repair
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US20020004101A1 (en) * 1995-04-19 2002-01-10 Schneider (Usa) Inc. Drug coating with topcoat
US5855612A (en) * 1995-05-12 1999-01-05 Ohta Inc. Biocompatible titanium implant
US5865814A (en) * 1995-06-07 1999-02-02 Medtronic, Inc. Blood contacting medical device and method
US5591199A (en) * 1995-06-07 1997-01-07 Porter; Christopher H. Curable fiber composite stent and delivery system
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US5888533A (en) * 1995-10-27 1999-03-30 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5607442A (en) * 1995-11-13 1997-03-04 Isostent, Inc. Stent with improved radiopacity and appearance characteristics
US5733326A (en) * 1996-05-28 1998-03-31 Cordis Corporation Composite material endoprosthesis
US5874165A (en) * 1996-06-03 1999-02-23 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto polymeric subtrates
US5855618A (en) * 1996-09-13 1999-01-05 Meadox Medicals, Inc. Polyurethanes grafted with polyethylene oxide chains containing covalently bonded heparin
US6676697B1 (en) * 1996-09-19 2004-01-13 Medinol Ltd. Stent with variable features to optimize support and method of making such stent
US5868781A (en) * 1996-10-22 1999-02-09 Scimed Life Systems, Inc. Locking stent
US5877263A (en) * 1996-11-25 1999-03-02 Meadox Medicals, Inc. Process for preparing polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents
US5741881A (en) * 1996-11-25 1998-04-21 Meadox Medicals, Inc. Process for preparing covalently bound-heparin containing polyurethane-peo-heparin coating compositions
US5728751A (en) * 1996-11-25 1998-03-17 Meadox Medicals, Inc. Bonding bio-active materials to substrate surfaces
US5733330A (en) * 1997-01-13 1998-03-31 Advanced Cardiovascular Systems, Inc. Balloon-expandable, crush-resistant locking stent
US5874101A (en) * 1997-04-14 1999-02-23 Usbiomaterials Corp. Bioactive-gel compositions and methods
US6042875A (en) * 1997-04-30 2000-03-28 Schneider (Usa) Inc. Drug-releasing coatings for medical devices
US5891192A (en) * 1997-05-22 1999-04-06 The Regents Of The University Of California Ion-implanted protein-coated intralumenal implants
US20020004060A1 (en) * 1997-07-18 2002-01-10 Bernd Heublein Metallic implant which is degradable in vivo
US6174330B1 (en) * 1997-08-01 2001-01-16 Schneider (Usa) Inc Bioabsorbable marker having radiopaque constituents
US6010445A (en) * 1997-09-11 2000-01-04 Implant Sciences Corporation Radioactive medical device and process
US6015541A (en) * 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
US6511748B1 (en) * 1998-01-06 2003-01-28 Aderans Research Institute, Inc. Bioabsorbable fibers and reinforced composites produced therefrom
US6709379B1 (en) * 1998-11-02 2004-03-23 Alcove Surfaces Gmbh Implant with cavities containing therapeutic agents
US6187045B1 (en) * 1999-02-10 2001-02-13 Thomas K. Fehring Enhanced biocompatible implants and alloys
US6183505B1 (en) * 1999-03-11 2001-02-06 Medtronic Ave, Inc. Method of stent retention to a delivery catheter balloon-braided retainers
US6177523B1 (en) * 1999-07-14 2001-01-23 Cardiotech International, Inc. Functionalized polyurethanes
US6706273B1 (en) * 1999-08-14 2004-03-16 Ivoclar Vivadent Ag Composition for implantation into the human and animal body
US6689375B1 (en) * 1999-11-09 2004-02-10 Coripharm Medizinprodukte Gmbh & Co. Kg Resorbable bone implant material and method for producing the same
US20020002399A1 (en) * 1999-12-22 2002-01-03 Huxel Shawn Thayer Removable stent for body lumens
US6537589B1 (en) * 2000-04-03 2003-03-25 Kyung Won Medical Co., Ltd. Calcium phosphate artificial bone as osteoconductive and biodegradable bone substitute material
US6527801B1 (en) * 2000-04-13 2003-03-04 Advanced Cardiovascular Systems, Inc. Biodegradable drug delivery material for stent
US7335314B2 (en) * 2000-09-28 2008-02-26 Advanced Cardiovascular Systems Inc. Method of making an implantable medical device
US20050033412A1 (en) * 2000-09-28 2005-02-10 Wu Steven Z. Method of making an implantable medical device
US6517888B1 (en) * 2000-11-28 2003-02-11 Scimed Life Systems, Inc. Method for manufacturing a medical device having a coated portion by laser ablation
US20030033001A1 (en) * 2001-02-27 2003-02-13 Keiji Igaki Stent holding member and stent feeding system
US20030039689A1 (en) * 2001-04-26 2003-02-27 Jianbing Chen Polymer-based, sustained release drug delivery system
US6679980B1 (en) * 2001-06-13 2004-01-20 Advanced Cardiovascular Systems, Inc. Apparatus for electropolishing a stent
US6695920B1 (en) * 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US20040030380A1 (en) * 2002-04-24 2004-02-12 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20040039441A1 (en) * 2002-05-20 2004-02-26 Rowland Stephen Maxwell Drug eluting implantable medical device
US6846323B2 (en) * 2003-05-15 2005-01-25 Advanced Cardiovascular Systems, Inc. Intravascular stent

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10064982B2 (en) * 2001-06-27 2018-09-04 Abbott Cardiovascular Systems Inc. PDLLA stent coating
US20150359943A1 (en) * 2001-06-27 2015-12-17 Abbott Cardiovascular Systems Inc. Pdlla stent coating
US8469968B2 (en) 2006-08-01 2013-06-25 Abbott Cardiovascular Systems Inc. Methods of treatment with drug delivery after biodegradation of the stent scaffolding
US8398706B2 (en) 2006-10-17 2013-03-19 Advanced Cardiovascular Systems, Inc. Drug delivery after biodegradation of the stent scaffolding
US20110190875A1 (en) * 2006-10-17 2011-08-04 Advanced Cardiovascular Systems, Inc. Drug Delivery After Biodegradation Of The Stent Scaffolding
US9090745B2 (en) 2007-06-29 2015-07-28 Abbott Cardiovascular Systems Inc. Biodegradable triblock copolymers for implantable devices
US9468707B2 (en) 2007-06-29 2016-10-18 Abbott Cardiovascular Systems Inc. Biodegradable triblock copolymers for implantable devices
US20090110713A1 (en) * 2007-10-31 2009-04-30 Florencia Lim Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices
US9592323B2 (en) 2008-05-21 2017-03-14 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
US20090291111A1 (en) * 2008-05-21 2009-11-26 Florencia Lim Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
US20100070013A1 (en) * 2008-09-18 2010-03-18 Medtronic Vascular, Inc. Medical Device With Microsphere Drug Delivery System
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
US8540765B2 (en) 2009-05-20 2013-09-24 480 Biomedical, Inc. Medical implant
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
US8137396B2 (en) * 2009-05-20 2012-03-20 480 Biomedical, Inc Medical implant
US9155638B2 (en) * 2009-05-20 2015-10-13 480 Biomedical, Inc. Drug eluting medical implant
US20110238162A1 (en) * 2009-05-20 2011-09-29 Arsenal Medical Medical implant
US20100298952A1 (en) * 2009-05-20 2010-11-25 Arsenal Medical Medical implant
US9278016B2 (en) 2009-05-20 2016-03-08 480 Biomedical, Inc. Medical implant
US10076591B2 (en) 2010-03-31 2018-09-18 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
US20130138219A1 (en) * 2011-11-28 2013-05-30 Cook Medical Technologies Llc Biodegradable stents having one or more coverings
US20140242144A1 (en) * 2012-02-10 2014-08-28 Abbott Cardiovascular Systems Inc. Drug eluting scaffold for kidney-related disease
US8840678B2 (en) * 2012-02-10 2014-09-23 Abbott Cardiovascular Systems Inc. Drug-eluting bioabsorbable renal artery stent for renal cancer and inflammatory disorders
WO2015160501A1 (en) 2014-04-18 2015-10-22 Auburn University Particulate vaccine formulations for inducing innate and adaptive immunity
WO2017049284A1 (en) * 2015-09-17 2017-03-23 Hollister Incorporated Scaffold-based wound care delivery system and method

Also Published As

Publication number Publication date Type
US20110190875A1 (en) 2011-08-04 application
US8398706B2 (en) 2013-03-19 grant

Similar Documents

Publication Publication Date Title
US7396539B1 (en) Stent coatings with engineered drug release rate
US20070110888A1 (en) Coated and imprinted medical devices and methods of making the same
US20050112170A1 (en) Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
US20100030183A1 (en) Method of treating vascular disease at a bifurcated vessel using a coated balloon
US7169404B2 (en) Biologically absorbable coatings for implantable devices and methods for fabricating the same
US20060093643A1 (en) Medical device for delivering therapeutic agents over different time periods
US20050214339A1 (en) Biologically degradable compositions for medical applications
US20090004243A1 (en) Biodegradable triblock copolymers for implantable devices
US20040098106A1 (en) Intraluminal prostheses and carbon dioxide-assisted methods of impregnating same with pharmacological agents
US20100023108A1 (en) Multiple Drug Delivery From A Balloon And A Prosthesis
US20050106204A1 (en) Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US20080215137A1 (en) Therapeutic driving layer for a medical device
US20100063570A1 (en) Coating on a balloon comprising a polymer and a drug
US20060002968A1 (en) Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US20080058919A1 (en) Composite polymeric and metallic stent with radiopacity
US20070134288A1 (en) Anti-adhesion agents for drug coatings
US20090306120A1 (en) Terpolymers containing lactide and glycolide
US20090285974A1 (en) Method for electrostatic coating of a medical device
US20100244329A1 (en) Medical Device with Regioselective Structure-Property Distribution
US7285287B2 (en) Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses
US20090110713A1 (en) Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices
US20060136048A1 (en) Abluminal, multilayer coating constructs for drug-delivery stents
US7824601B1 (en) Process of making a tubular implantable medical device
US20100004734A1 (en) Stent fabrication via tubular casting processes
Puranik et al. Recent advances in drug eluting stents

Legal Events

Date Code Title Description
AS Assignment

Owner name: ADVANCED CARDIOVASCULAR SYSTEMS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GALE, DAVID C.;HUANG, BIN;REEL/FRAME:018805/0969

Effective date: 20070108